 |
|
Recurrent Gustatory Sweating (Frey Syndrome) After Intracutaneous Injection of Botulinum Toxin Type A
Incidence, Management, and Outcome
Ollivier Laccourreye, MD;
Elie Akl, MD;
Raimundo Gutierrez-Fonseca, MD;
Dominique Garcia, MD;
Daniel Brasnu, MD;
Brigitte Bonan
Arch Otolaryngol Head Neck Surg. 1999;125:283-286.
Objective To evaluate the duration of effectiveness of intracutaneous injection of botulinum toxin type A for gustatory sweating as well as the incidence, severity, management, and outcome of recurrent gustatory sweating.
Design An inception cohort with a minimum of 18 months of follow-up.
Setting A tertiary care center and university teaching hospital.
Patients Thirty-three patients with severe gustatory sweating.
Intervention Intracutaneous injection of 25 to 175 IU (mean, 86 IU) of botulinum toxin type A.
Main Outcome Measures Analysis of the effectiveness of the intracutaneous injection of botulinum toxin type A using the Kaplan-Meier actuarial life-table method; completion of the Minor starch-iodine test in patients without symptomatic recurrent gustatory sweating; and the patients' self-assessment of the severity of the recurrent gustatory sweating.
Results The 1-, 2-, and 3-year actuarial estimate for symptomatic recurrent gustatory sweating was 27%, 63%, and 92%, respectively. In the 7 patients without symptomatic recurrent gustatory sweating, the Minor starch-iodine test revealed persistent gustatory sweating in 6, resulting in an overall 97% rate (32 of 33 patients) for recurrent gustatory sweating. No statistical relationship could be demonstrated between the duration of effectiveness, the incidence of recurrent gustatory sweating, the severity of recurrent gustatory sweating, and the following variables: age, sex, cause of gustatory sweating, skin surface involved, and dose of botulinum toxin type A injection. Within the group of 26 patients with symptomatic recurrent gustatory sweating, (1) the severity of the recurrent gustatory sweating was always reduced when compared with the severity of the initial gustatory sweating, and (2) the recurrent gustatory sweating always remained amenable to reinjection of botulinum toxin type A.
Conclusions The present series demonstrated a linear regression in the effectiveness of the intracutaneous injection of botulinum toxin type A in patients with gustatory sweating, while no factors appeared to be statistically related to the duration of effectiveness and/or the incidence of recurrent gustatory sweating. However, because the severity of recurrent gustatory sweating is reduced when compared with the severity of the initial gustatory sweating and because recurrent gustatory sweating remains amenable to reinjection of botulinum toxin type A, we believe that the intracutaneous injection of botulinum toxin type A should become the first-line treatment option in patients with gustatory sweating.
From the Departments of Otorhinolaryngology–Head and Neck Surgery (Drs Laccourreye, Akl, Gutierrez-Fonseca, Garcia, and Brasnu) and Pharmacology (Ms Bonan), Hôpital Laënnec, Assistance Publique Hôpitaux de Paris, University Paris V, Paris, France.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Naumann et al.
Neurology 2008;70:1707-1714.
ABSTRACT
| FULL TEXT
A Pilot Study Evaluating the Treatment of Postparotidectomy Sialoceles With Botulinum Toxin Type A
Vargas et al.
Arch Otolaryngol Head Neck Surg 2000;126:421-424.
ABSTRACT
| FULL TEXT
|
